Status:
UNKNOWN
Tamoxifen Pharmacogenetics in Asian Breast Cancer Women
Lead Sponsor:
Inje University
Conditions:
Poisoning by, Adverse Effect of and Underdosing of Tamoxifen
Eligibility:
FEMALE
18+ years
Brief Summary
The clinical outcome of tamoxifen treatment in breast cancer patients may be influenced by the activity of cytochrome P450 enzymes involving in tamoxifen biotransformation.
Detailed Description
The investigators investigated the prognostic and/or predictive value of genetic polymorphisms of enzymes involved in tamoxifen metabolism for the treatment outcome among Asian breast cancer patients.
Eligibility Criteria
Inclusion
- incident breast cancer patients who underwent surgery
Exclusion
- previous cancer history before breast cancer diagnosis
Key Trial Info
Start Date :
August 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2015
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT01181518
Start Date
August 1 2010
End Date
December 1 2015
Last Update
June 3 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Inje University
Busan, Busan, South Korea, 614-735